# OnCo record glofitamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/glofitamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "glofitamab" ;
  schema:name "Glofitamab"@en ;
  schema:description "Glofitamab is a fixed-duration bispecific for large B-cell lymphoma, with OS benefit when combined with chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/glofitamab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Glofitamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q117846135> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Glofitamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (CD20×CD3, 2:1)" ;
  schema:alternateName "Columvi" ;
  onco:approval "US 2023: Relapsed/refractory DLBCL after ≥2 lines (accelerated)" ;
  onco:acceleratedApproval "US 2023-06-15: Relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct04077723/>, <https://onco.cc/trials/nct06090539/>, <https://onco.cc/trials/nct05533775/>, <https://onco.cc/trials/nct06534437/>, <https://onco.cc/trials/nct03075696/>, <https://onco.cc/trials/nct06084936/>, <https://onco.cc/trials/nct06634589/>, <https://onco.cc/trials/nct03533283/>, <https://onco.cc/trials/nct06806033/>, <https://onco.cc/trials/nct04980222/> .